Compare
Camp4 Therapeutics Corp vs China Pharma Holdings, Inc. vs Upstream Bio, Inc. vs ProPhase Labs, Inc.
| Latest fiscal year | Camp4 Therapeutics Corp CAMP | China Pharma Holdings, Inc. CPHI | Upstream Bio, Inc. UPB | ProPhase Labs, Inc. PRPH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.50M | $4.14M | $2.85M | $4.34M |
| Revenue growth (YoY) | +436.5% | -8.5% | +20.4% | -35.8% |
| Gross margin | n/a | -3.2% | n/a | 31.9% |
| Operating margin | n/m | -78.2% | n/m | -415.4% |
| Net margin | n/m | -76.9% | n/m | -339.3% |
| Net income | -$80.40M | -$3.19M | -$143.44M | -$14.74M |
| EPS (Diluted) | -$2.65 | -$0.74 | -$2.66 | -$1.74 |
| Operating cash flow | -$29.55M | $148.3K | -$133.28M | -$8.34M |
| Free cash flow | -$29.83M | $88.9K | -$133.44M | -$8.34M |
| Cash & equivalents | $109.52M | $345.1K | $101.58M | $90.0K |
| Total assets | $117.81M | $31.00M | $353.77M | $59.87M |
| Total liabilities | $70.10M | $8.26M | $14.00M | $56.36M |
| Shareholders' equity | $47.70M | $22.74M | $339.77M | $3.51M |
| Return on year-end equity | -168.5% | -14.0% | -42.2% | -420.3% |
| Shares outstanding | 51.90M | 15.52M | 54.24M | 8.97M |
Revenue, most recent five fiscal years
| Fiscal year | Camp4 Therapeutics Corp | China Pharma Holdings, Inc. | Upstream Bio, Inc. | ProPhase Labs, Inc. |
|---|---|---|---|---|
| Latest | $3.50M Ended 2025-12-31 | $4.14M Ended 2025-12-31 | $2.85M Ended 2025-12-31 | $4.34M Ended 2025-12-31 |
| 1 year earlier | $652.0K Ended 2024-12-31 | $4.53M Ended 2024-12-31 | $2.37M Ended 2024-12-31 | $6.77M Ended 2024-12-31 |
| 2 years earlier | $350.0K Ended 2023-12-31 | $7.01M Ended 2023-12-31 | $2.38M Ended 2023-12-31 | $34.98M Ended 2023-12-31 |
| 3 years earlier | n/a | $8.10M Ended 2022-12-31 | n/a | $122.65M Ended 2022-12-31 |
| 4 years earlier | n/a | $9.64M Ended 2021-12-31 | n/a | $79.04M Ended 2021-12-31 |